Pharmaceutical Raw Materials

Daphosphatin is a kind of nucleophilic sulfur-containing precursor drug, which plays a role in dephosphorylation by membrane alkaline phosphatase to be an active metabolite WR-1065 (free mercaptan). Daphosphatine is a normal cell protective agent, mainly used in the auxiliary treatment of various cancers. The use of this product before chemotherapy in patients with lung cancer, ovarian cancer, breast cancer, nasopharyngeal carcinoma, bone tumors, gastrointestinal tumors and hematological malignancies can significantly reduce the toxicity of chemotherapeutic drugs to the kidneys, bone marrow, heart, ears and nervous system, without lowering the efficacy of chemotherapeutic drugs. The use of this product before radiotherapy can significantly reduce the occurrence of dry mouth and mucositis.

Pimochet is also called pimochet. Pimozide is a diphenylbutylpyridine antipsychotic. It has a good effect on mania, hallucination, delusion, indifference and withdrawal, especially for patients with chronic withdrawal. The drug also has some degree of calcium antagonism. The indications are applicable to acute and chronic schizophrenia, paranoid state, single symptom hypochondriasis and Tourette syndrome.

Rubber and pharmaceutical industries. Antidote for heavy metal poisoning.

Befiradol (F-13,640; NLX-112) is a very potent and highly selective 5-HT1A receptor full agonist. It has powerful analgesic and antiallodynic effects comparable to those of high doses of opioid painkillers, but with fewer and less prominent side effects, as well as little or no development of tolerance with repeated use. A SAR study revealed that replacement of the dihalophenyl moiety by 3-benzothienyl increases maximal efficacy from 84% to 124% (Ki=2.7 nM). Befiradol was discovered and developed by Pierre Fabre Médicament, a French pharmaceuticals company. In September 2013, befiradol was out-licensed to Neurolixis, a California-based biotechnology company. Neurolixis announced that it intends to re-purpose befiradol for the treatment of Levodopa-induced dyskinesia in Parkinson's disease. In support of this indication, preclinical data was published describing the activity of befiradol in animal models of Parkinson's disease.

Daunorubicin is an anthracycline antibiotic that has antineoplastic activity and is used in the therapy of acute leukemia and AIDS related Kaposi sarcoma. Daunorubicin is associated with a low rate of transient serum enzyme and bilirubin elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury with jaundice.